Romidepsin Plus CHOP in Previously Untreated Peripheral T-Cell Lymphoma Final Analysis of Ro-CHOP Trial – The ASCO Post
As reported in the Journal of Clinical Oncology by Camus et al, the final analysis of the phase III Ro-CHOP trial showed no significant progression-free or overall survival benefit with the addition of romidepsin (Ro) to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) in previously untreated patients with peripheral T-cell lymphoma (PTCL). In the international open-label study, 421 patients were randomly assigned between January 2013 and December 2017 to receive Ro-CHOP (n = 211) or CHOP (n